Vaxcyte (PCVX) Common Equity (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Common Equity data on file, last reported at $3.0 billion in Q1 2026.

• Common Equity for Q1 2026 came in at $3.0 billion, down 6.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.0 billion (down 6.38% YoY), and the FY2025 annual result was $2.7 billion, down 18.76% from the prior year.
• Common Equity rose to $3.0 billion in Q1 2026 per PCVX's latest filing, from $2.7 billion in the prior quarter.
• Over five years, Common Equity peaked at $3.4 billion in Q3 2024 and troughed at $359.3 million in Q3 2022.
• A 5-year average of $1.9 billion and a median of $2.0 billion in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2025: Common Equity soared 291.1% in 2023, then retreated 18.76% in 2025.
• A 5-year view of Common Equity shows it stood at $953.6 million in 2022, then jumped by 30.08% to $1.2 billion in 2023, then soared by 166.5% to $3.3 billion in 2024, then dropped by 18.76% to $2.7 billion in 2025, then grew by 11.56% to $3.0 billion in 2026.
• Business Quant data shows PCVX's Common Equity at $3.0 billion in Q1 2026, $2.7 billion in Q4 2025, and $2.9 billion in Q3 2025.